Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session

RATIONALE: A substantial number of breast cancer patients with an overexpression of the human epidermal growth factor receptor 2 (HER2) have residual disease after neoadjuvant therapy or become resistant to trastuzumab. Photodynamic therapy (PDT) using nanobodies targeted to HER2 is a promising trea...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Control Release
Главные авторы: Deken, Marion M., Kijanka, Marta M., Hernández, Irati Beltrán, Slooter, Maxime D., de Bruijn, Henriette S., van Diest, Paul J., van Bergen en Henegouwen, Paul M.P., Lowik, Clemens W.G.M., Robinson, Dominic J., Vahrmeijer, Alexander L., Oliveira, Sabrina
Формат: Artigo
Язык:Inglês
Опубликовано: 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7116241/
https://ncbi.nlm.nih.gov/pubmed/32330574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2020.04.030
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы